12/20
02:03 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
12/12
02:03 am
gsk
GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
12/9
01:38 pm
gsk
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
Low
Report
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
12/4
11:21 pm
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/15
08:17 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.
11/12
08:03 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.
10/31
07:10 am
gsk
GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Low
Report
GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
10/26
09:32 am
gsk
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]
Low
Report
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]
10/24
07:00 am
gsk
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
Low
Report
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
10/8
07:00 am
gsk
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
Low
Report
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons